COVID antibody treatments show promise for preventing severe disease.

  title={COVID antibody treatments show promise for preventing severe disease.},
  author={Heidi Ledford},
A New Approach to the Management of COVID-19. Antagonists of IL-6: Siltuximab
Since the beginning of the pandemic, numerous national and international clinical trials have been conducted with a large number of drugs. Many of them are intended for the treatment of other
Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial
It is hypothesized this probiotic primarily acts by interacting with the host’s immune system rather than changing colonic microbiota composition, and probiotic supplementation significantly increased specific IgM and IgG against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) compared to placebo.
Bamlanivimab use in mild‐to‐moderate COVID‐19 disease: A matched cohort design
BAM infusion for mild-to-moderate Sars-CoV-2 infection in outpatients significantly prevented subsequent ED visits, hospitalizations, and death from SARS-Cov-2.
Contributions of single-particle cryoelectron microscopy toward fighting COVID-19
Single-particle cryo-electron microscopy studies have furthered the understanding of spike protein-ACE2 receptor interactions, which has informed the design of effective vaccines and to the characterization of neutralizing antibody binding sites, which will lead to theDesign of novel therapeutics as the virus evolves.
MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants
This study generated a humanized monoclonal antibody that could effectively neutralize live viruses, with an EC50 of 92 pM, and exhibited effective Fc-mediated functions against the alpha, beta, and gamma variants of SARS-CoV-2.
Personal observations on COVID-19 and the conduct and application of biomedical science
  • J. C. Smith, D. Goodhew
  • Medicine
    Interface Focus
  • 2021
Observations of the ways in which the conduct of research has changed during the COVID-19 pandemic and the quality of the scientific advice provided to UK citizens, and especially to schools are described.
Potential drugs against COVID-19 revealed by gene expression profile, molecular docking and molecular dynamic simulation
Several drugs that could act on the biological pathways altered in COVID-19, an emerging betacoronavirus, are suggested that could be efficient in treating the causative agent of the virus.
Surface Glycan Modification of Cellular Nanosponges to Promote SARS-CoV-2 Inhibition
Overall, surface glycan engineering of host-mimicking cellular nanosponges is a facile method to enhance SARS-CoV-2 inhibition and can be readily generalized to promote the inhibition of other glycan-dependent viruses.


The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2
Data indicate that VIR-7831 and Vir-7832 are key agents in the fight against COVID-19, as they retain activity against monoclonal antibody resistance mutations conferring reduced susceptibility to currently authorized mAbs.